Serum Ferritin as a Predictor of Treatment Outcome in Patients With Chronic Hepatitis C

Ferrara, Francesca; Ventura, Paolo; Vegetti, Alberto; Guido, Maria; Abbati, G.; Corradini, Elena; Fattovich, Giovanna; Ferrari, Carlo; Tagliazucchi, Mara; Carbonieri, Anna; Orlandini, A.; Fagiuoli, Stefano; Boninsegna, Sara; Minola, E.; Rizzo, Giovanna; Belussi, F.; Felder, Martina; Massari, Marco; Pozzato, Gabriele; Bonetto, Stefania; Rovere, Pierangelo; Sardini, C.; Borghi, A.; Zeneroli, Maria Luisa; Toniutto, Pierluigi; Rossi, Elisabetta; Pietrangelo, Antonello

doi:10.1038/ajg.2008.126

Cited by 34 publications

(25 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The increased ratio of serum ferritin (serum ferritin/ baseline ferritin ratio) in SVR subjects was significantly higher than in non-SVR individuals. A similar report has been previously published, and its results correspond with what we are reporting here [18] .…”

Section: Discussionsupporting

confidence: 82%

“…Though we did not investigate parameters involving hemolysis or RBV concentration, the correlation between rising levels of ferritin and the rate of SVR may be related to RBV-induced hemolysis and/or RBV concentration. Ferrara et al [18] considered that the rise of serum ferritin correlated to RBV-induced hemolysis at earlier phases of treatment, but the correlation between serum ferritin levels and hemolysis is lost at later phases of treatment. Therefore, they considered that elevated serum ferritin at a later phase might be caused by a reactive response from activated macrophages to interferon [18] .…”

Section: Discussionmentioning

confidence: 99%

“…Ferrara et al [18] considered that the rise of serum ferritin correlated to RBV-induced hemolysis at earlier phases of treatment, but the correlation between serum ferritin levels and hemolysis is lost at later phases of treatment. Therefore, they considered that elevated serum ferritin at a later phase might be caused by a reactive response from activated macrophages to interferon [18] . Their hypothesis that elevation of serum ferritin level during the PEG-IFN and RBV combination therapy might be caused not only by RBV-induced hemolysis but also by IFN is quite reasonable, because elevation of serum ferritin levels is also observed in PEG-IFN ␣ -2a monotherapy [13] .…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

PEG-IFNα/RBV Combination Therapy for Chronic Hepatitis C Patients Increases Serum Ferritin Level while It Improves Sustained Viral Response Rate

Yada

Kudo²,

Chung³

et al. 2010

Intervirology

View full text Add to dashboard Cite

Objectives: We investigated the significance of serum ferritin levels in pegylated interferon (PEG-IFN) and ribavirin (RBV) combination therapy for chronic hepatitis C (CHC) and examined its correlation with serum alanine aminotransferase (ALT) levels during therapy and response to the therapy. Methods: A total of 175 patients with CHC received the combination therapy. Correlations between serum ferritin levels and serum ALT levels at 12 and 24 weeks of therapy were examined. Differences in serum ferritin levels during therapy between patients with sustained viral response (SVR) and non-SVR were also examined. Results: Only 24 (13.7%) and 20 (11.4%) patients showed elevated serum ALT levels (≧70 IU/l) at 12 and 24 weeks of therapy, respectively. There was no correlation between serum ferritin levels and ALT levels. Ninety-five (54.3%) of 175 patients achieved SVR. Serum ferritin levels increased dramatically in both SVR and non-SVR groups after starting the therapy and were significantly higher in the SVR group throughout the therapy. Conclusions: Serum ferritin level increases during PEG-IFN and RBV combination therapy; however, it did not correlate with either serum ALT level or the total dose of RBV. Higher serum ferritin levels during combination therapy appear to be associated with favorable therapeutic response.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

PEG-IFNα/RBV Combination Therapy for Chronic Hepatitis C Patients Increases Serum Ferritin Level while It Improves Sustained Viral Response Rate

Yada

Kudo²,

Chung³

et al. 2010

Intervirology

View full text Add to dashboard Cite

show abstract

“…It has long been recognized that iron overload promotes hepatic fibrosis in hereditary hemochromatosis (reviewed by Drakesmith and Prentice, 2008). Serum iron stores are increased frequently in patients with chronic hepatitis C and elevated hepatic iron concentration has been associated with a poor response to interferon alfa [Ferrara et al, 2009]. In the present study, HFE gene mutations were assessed retrospectively in a large cohort of well-characterized chronic hepatitis C patients.…”

Section: Discussionmentioning

confidence: 98%

“…Patients with the C282Y mutation had more-advanced hepatic fibrosis and decompensated liver disease more frequently in the case of concomitant chronic hepatitis C than patients without this mutation [Hezode et al, 1999;Bonkovsky et al, 2002;Erhardt et al, 2003;Pacal et al, 2007;Won et al, 2009]. Recently, Ferrara et al [2009] showed that serum ferritin is a predictor of treatment outcome in patients with chronic hepatitis C.…”

Section: Introductionmentioning

confidence: 96%

Influence of mutation of the HFE gene on the progression of chronic viral hepatitis B and C in Moroccan patients

Ezzikouri

Rebbani

Ababou

et al. 2011

Journal of Medical Virology

View full text Add to dashboard Cite

The implication of hemochromatosis (HFE) gene mutations in chronic viral hepatitis remains controversial. The aim of the present study was to measure the frequencies of the common HFE gene mutations in Moroccan subjects with chronic viral hepatitis B and C and to assess their influence on the progression of liver disease. H63D and C282Y mutations were screened by the polymerase chain reaction followed by restriction fragment length polymorphism analysis in 170 chronic hepatitis B patients, 168 chronic hepatitis C patients, and 200 healthy controls. A very small proportion of patients infected with hepatitis B virus (HBV) or hepatitis C virus (HCV; 1.8% and none, respectively) were heterozygous for the C282Y mutation, that is, rates not statistically different from those observed in healthy control (2%, P > 0.05). Similarly, the frequency of the H63D allele was not significantly different between HBV (13.8%) or HCV (14.3%) patients and controls (13.5%, P > 0.05). Multivariate analysis showed that carriers of the H63D mutation infected with HBV are at higher risk to progress towards an advanced liver disease when compared with patients infected with HBV with wild-type (OR = 2.45, 95% CI = 1.07-5.58). In contrast, no association between HFE mutated HCV-infected patients and an increased risk of disease progression was found (OR = 1.24, 95% CI = 0.61-2.50, P = 0.547). In conclusion, in Morocco the frequency of the HFE C282Y allele is very low and H63D mutation carriage occurs in almost 14% of the patients, a rate similar in chronic hepatitis patients and healthy controls. In the case of chronic hepatitis B, the carriage of the H63D variant represents a risk factor of evolution towards a more active disease.

show abstract

HCV and Iron Excess: The Interaction and how to Handle it

Maliken

Kowdley

2010

Clinical Dilemmas in Viral Liver Disease

View full text Add to dashboard Cite

Serum Ferritin as a Predictor of Treatment Outcome in Patients With Chronic Hepatitis C

Cited by 34 publications

References 40 publications

PEG-IFNα/RBV Combination Therapy for Chronic Hepatitis C Patients Increases Serum Ferritin Level while It Improves Sustained Viral Response Rate

PEG-IFNα/RBV Combination Therapy for Chronic Hepatitis C Patients Increases Serum Ferritin Level while It Improves Sustained Viral Response Rate

Influence of mutation of the HFE gene on the progression of chronic viral hepatitis B and C in Moroccan patients

HCV and Iron Excess: The Interaction and how to Handle it

Contact Info

Product

Resources

About